WO2016103269A8 - Populations of neural progenitor cells and methods of producing and using same - Google Patents

Populations of neural progenitor cells and methods of producing and using same Download PDF

Info

Publication number
WO2016103269A8
WO2016103269A8 PCT/IL2015/051253 IL2015051253W WO2016103269A8 WO 2016103269 A8 WO2016103269 A8 WO 2016103269A8 IL 2015051253 W IL2015051253 W IL 2015051253W WO 2016103269 A8 WO2016103269 A8 WO 2016103269A8
Authority
WO
WIPO (PCT)
Prior art keywords
cells
populations
methods
producing
neural progenitor
Prior art date
Application number
PCT/IL2015/051253
Other languages
French (fr)
Other versions
WO2016103269A1 (en
Inventor
Yechiel ELKABETZ
Reuven EDRI
Yakey YAFFE
Alexander Meissner
Michael J. ZILLER
Original Assignee
Ramot At Tel-Aviv University Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ramot At Tel-Aviv University Ltd. filed Critical Ramot At Tel-Aviv University Ltd.
Publication of WO2016103269A1 publication Critical patent/WO2016103269A1/en
Publication of WO2016103269A8 publication Critical patent/WO2016103269A8/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C12N5/0619—Neurons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0618—Cells of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/11—Epidermal growth factor [EGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/119—Other fibroblast growth factors, e.g. FGF-4, FGF-8, FGF-10
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/13—Nerve growth factor [NGF]; Brain-derived neurotrophic factor [BDNF]; Cilliary neurotrophic factor [CNTF]; Glial-derived neurotrophic factor [GDNF]; Neurotrophins [NT]; Neuregulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/41—Hedgehog proteins; Cyclopamine (inhibitor)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/40—Regulators of development
    • C12N2501/42—Notch; Delta; Jagged; Serrate
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/999—Small molecules not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/02—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from embryonic cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Neurology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

An isolated population of cells is provided the cells comprise at least 10 % HES5+ cells, wherein said HES5+ cells are: (i) early radial glial (E -RG) cells; (ii) mid radial glial (M-RG) cells; (iii) late radial glial (L-RG) cells; or (iv) long term neural progenitor (LNP) cells. Also provided are additional populations of neural cells and use of the populations and methods of producing same.
PCT/IL2015/051253 2014-12-23 2015-12-23 Populations of neural progenitor cells and methods of producing and using same WO2016103269A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462096184P 2014-12-23 2014-12-23
US62/096,184 2014-12-23

Publications (2)

Publication Number Publication Date
WO2016103269A1 WO2016103269A1 (en) 2016-06-30
WO2016103269A8 true WO2016103269A8 (en) 2016-08-25

Family

ID=55182518

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IL2015/051253 WO2016103269A1 (en) 2014-12-23 2015-12-23 Populations of neural progenitor cells and methods of producing and using same

Country Status (1)

Country Link
WO (1) WO2016103269A1 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070655A (en) * 2017-09-21 2018-05-25 北京旌准医疗科技有限公司 For predicting the kit of risk of hepatic cancer and method

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9719068B2 (en) 2010-05-06 2017-08-01 Children's Hospital Medical Center Methods and systems for converting precursor cells into intestinal tissues through directed differentiation
CN106661548B (en) 2014-05-28 2020-12-11 儿童医院医疗中心 Methods and systems for converting precursor cells to stomach tissue via directed differentiation
AU2015331848B2 (en) 2014-10-17 2022-03-03 Children's Hospital Medical Center, D/B/A Cincinnati Children's Hospital Medical Center In vivo model of human small intestine using pluripotent stem cells and methods of making and using same
CN109219657A (en) 2016-03-30 2019-01-15 阿斯特利亚斯生物治疗股份公司 Oligodendrocyte progenitor cells composition
CA3016641A1 (en) 2016-05-05 2017-11-09 Children's Hospital Medical Center Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same
US11845960B2 (en) 2016-09-12 2023-12-19 President And Fellows Of Harvard College Transcription factors controlling differentiation of stem cells
KR102087294B1 (en) * 2016-11-15 2020-03-10 한국생명공학연구원 A method for preparing the Parkinson's disease model comprising 3D intestinal organoid and 3D neuro ectodermal sphere, and use thereof
KR102558606B1 (en) 2016-12-05 2023-07-26 칠드런즈 호스피탈 메디칼 센터 Colon organ organ and methods of making and using the same
JP7471084B2 (en) * 2017-03-21 2024-04-19 メモリアル スローン ケタリング キャンサー センター Stem cell derived astrocytes, methods of making and using
TWI649467B (en) * 2017-04-12 2019-02-01 中央研究院 Kit for selecting neurological drug and uses thereof
TWI793151B (en) 2017-08-23 2023-02-21 瑞士商諾華公司 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
MX2020005668A (en) 2017-11-30 2020-11-24 Univ Kyoto Method for culture of cells.
WO2019108894A1 (en) 2017-12-01 2019-06-06 President And Fellows Of Harvard College Methods and compositions for the production of oligodendrocyte progenitor cells
WO2019195675A1 (en) 2018-04-06 2019-10-10 President And Fellows Of Harvard College Methods of identifying combinations of transcription factors
EP3781675A1 (en) * 2018-04-20 2021-02-24 FUJIFILM Cellular Dynamics, Inc. Method for differentiation of ocular cells and use thereof
AR116109A1 (en) 2018-07-10 2021-03-31 Novartis Ag DERIVATIVES OF 3- (5-AMINO-1-OXOISOINDOLIN-2-IL) PIPERIDINE-2,6-DIONA AND USES OF THE SAME
HUE063715T2 (en) 2018-07-10 2024-01-28 Novartis Ag 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and their use in the treatment of ikaros family zinc finger 2 (ikzf2)-dependent diseases
US20200087622A1 (en) * 2018-09-19 2020-03-19 Lineage Cell Therapeutics, Inc. Methods for differentiating pluripotent stem cells in dynamic suspension culture
CN113260703A (en) * 2018-12-24 2021-08-13 黄海东 Mutant human 2Ig-B7-H3 protein coding gene, recombinant vector, host cell containing same, pharmaceutical composition and application thereof
WO2020154533A1 (en) 2019-01-23 2020-07-30 Asterias Biotherapeutics, Inc. Dorsally-derived oligodendrocyte progenitor cells from human pluripotent stem cells
CN110558279B (en) * 2019-09-16 2021-11-16 南方科技大学 Drug screening model, drug screening method and application thereof
CN112546199A (en) * 2019-09-25 2021-03-26 军事科学院军事医学研究院生物医学分析中心 LPAR1 coordinates ciliogenesis and neurogenesis during cortical development
JP2023516910A (en) * 2020-02-21 2023-04-21 アメリカ合衆国 Differentiation of radial glia and astrocytes from human pluripotent stem cells
KR102534488B1 (en) * 2020-09-10 2023-05-22 고려대학교 산학협력단 Efficient and short-term method for generating functional astrocytes
CN112522425B (en) * 2020-12-25 2023-11-28 武汉睿健医药科技有限公司 Marker gene for DPC cell identification and classification, screening method and application
WO2023283631A2 (en) * 2021-07-08 2023-01-12 The Broad Institute, Inc. Methods for differentiating and screening stem cells
EP4423252A1 (en) * 2021-10-29 2024-09-04 Trailhead Biosystems Inc. Methods and compositions for generating human forebrain neural progenitor cells and for maturation thereof to parvalbumin+ interneurons
WO2023118101A1 (en) * 2021-12-21 2023-06-29 Novo Nordisk A/S Stacked bmp inhibition for neural induction of pluripotent stem cells
CN114525241B (en) * 2021-12-31 2023-06-20 中国人民解放军军事科学院军事医学研究院 Application of SAFit2 and culture medium in promoting differentiation of human induced pluripotent stem cells to dopaminergic neurons
EP4239061A1 (en) * 2022-03-03 2023-09-06 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Method for the generation of outer radial glial (org) cells
CN115074327B (en) * 2022-06-24 2023-10-27 北京慧心医谷生物科技有限责任公司 Spinal cord progenitor cells for treating amyotrophic lateral sclerosis, and induced differentiation method and application thereof
CN116555260B (en) * 2023-04-24 2024-05-28 中山大学中山眼科中心 Method for preparing neural stem cells by carrying out gene editing on human iPSCs

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL154600B (en) 1971-02-10 1977-09-15 Organon Nv METHOD FOR THE DETERMINATION AND DETERMINATION OF SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES.
NL154598B (en) 1970-11-10 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING LOW MOLECULAR COMPOUNDS AND PROTEINS THAT CAN SPECIFICALLY BIND THESE COMPOUNDS AND TEST PACKAGING.
NL154599B (en) 1970-12-28 1977-09-15 Organon Nv PROCEDURE FOR DETERMINING AND DETERMINING SPECIFIC BINDING PROTEINS AND THEIR CORRESPONDING BINDABLE SUBSTANCES, AND TEST PACKAGING.
US3901654A (en) 1971-06-21 1975-08-26 Biological Developments Receptor assays of biologically active compounds employing biologically specific receptors
US3853987A (en) 1971-09-01 1974-12-10 W Dreyer Immunological reagent and radioimmuno assay
US3867517A (en) 1971-12-21 1975-02-18 Abbott Lab Direct radioimmunoassay for antigens and their antibodies
NL171930C (en) 1972-05-11 1983-06-01 Akzo Nv METHOD FOR DETERMINING AND DETERMINING BITES AND TEST PACKAGING.
US3850578A (en) 1973-03-12 1974-11-26 H Mcconnell Process for assaying for biologically active molecules
US3935074A (en) 1973-12-17 1976-01-27 Syva Company Antibody steric hindrance immunoassay with two antibodies
US3996345A (en) 1974-08-12 1976-12-07 Syva Company Fluorescence quenching with immunological pairs in immunoassays
US4034074A (en) 1974-09-19 1977-07-05 The Board Of Trustees Of Leland Stanford Junior University Universal reagent 2-site immunoradiometric assay using labelled anti (IgG)
US3984533A (en) 1975-11-13 1976-10-05 General Electric Company Electrophoretic method of detecting antigen-antibody reaction
US4098876A (en) 1976-10-26 1978-07-04 Corning Glass Works Reverse sandwich immunoassay
US4879219A (en) 1980-09-19 1989-11-07 General Hospital Corporation Immunoassay utilizing monoclonal high affinity IgM antibodies
US5011771A (en) 1984-04-12 1991-04-30 The General Hospital Corporation Multiepitopic immunometric assay
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5486359A (en) 1990-11-16 1996-01-23 Osiris Therapeutics, Inc. Human mesenchymal stem cells
US5281521A (en) 1992-07-20 1994-01-25 The Trustees Of The University Of Pennsylvania Modified avidin-biotin technique
US5843780A (en) 1995-01-20 1998-12-01 Wisconsin Alumni Research Foundation Primate embryonic stem cells
US6090622A (en) 1997-03-31 2000-07-18 The Johns Hopkins School Of Medicine Human embryonic pluripotent germ cells
US8354277B2 (en) 2004-10-12 2013-01-15 Technion Research & Development Foundation Ltd. Isolated primate embryonic cells derived from extended blastocysts
GB0504881D0 (en) * 2005-03-09 2005-04-13 Univ Edinburgh Directed neural differentiation

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108070655A (en) * 2017-09-21 2018-05-25 北京旌准医疗科技有限公司 For predicting the kit of risk of hepatic cancer and method

Also Published As

Publication number Publication date
WO2016103269A1 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
WO2016103269A8 (en) Populations of neural progenitor cells and methods of producing and using same
JOP20190161A1 (en) Near-ir glucose sensors
WO2018190719A3 (en) Anti-sirp alpha antibodies
EP3577213A4 (en) Microbial cells, methods of producing the same, and uses thereof
WO2016154579A3 (en) Crispr/cas-mediated gene conversion
WO2017030823A3 (en) Anti-tigit antibodies
WO2015200902A8 (en) Endophytes, associated compositions, and methods of use thereof
PH12017501218A1 (en) Rpe cell populations and methods of generating same
WO2015002724A3 (en) SC-β CELLS AND COMPOSITIONS AND METHODS FOR GENERATING THE SAME
IL288558B (en) Methods of use of purified hydrogen peroxide gas in agricultural production, transport, and storage
MY201637A (en) Natural killer cells and ilc3 cells and uses thereof
EP4292600A3 (en) Photoreceptors and photoreceptor progenitors produced from pluripotent stem cells
WO2020236972A3 (en) Non-classi engineered crispr-cas polynucleotide targeting system
WO2015149034A3 (en) Gene fusions and gene variants associated with cancer
WO2017214170A3 (en) Baff-r antibodies and uses thereof
WO2017087916A3 (en) Thermostable glucose biosensors and uses thereof
EP3277820A4 (en) Methods for producing modified red blood cell compositions, compositions and uses thereof
WO2015058132A3 (en) Anti-rsp02 and/or anti-rsp03 antibodies and their uses
EP3325608A4 (en) Methods and microorganisms for the production of 1,3-butanediol
WO2019224713A3 (en) Monospecific and multispecific anti-tmeff2 antibodies and there uses
WO2015138532A3 (en) Methods for the treatment of kidney fibrosis
EP3452084A4 (en) Anti-kv1.3 antibodies, and methods of production and use thereof
EP3401991A4 (en) System and method for producing 3.5-valent highly pure vanadium electrolyte
WO2019048930A3 (en) Bacteriophage for modulating inflammatory bowel disease
WO2019194875A3 (en) Oxidase-based sensors and methods of using

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 15826192

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 15826192

Country of ref document: EP

Kind code of ref document: A1